Literature DB >> 12788062

Serum response factor is modulated by the SUMO-1 conjugation system.

Kazuhito Matsuzaki1, Takeshi Minami, Masahide Tojo, Yoshiomi Honda, Yasuhiro Uchimura, Hisato Saitoh, Hideyo Yasuda, Shinji Nagahiro, Hideyuki Saya, Mitsuyoshi Nakao.   

Abstract

Serum stimulation leads to activation of the serum response factor (SRF)-mediated transcription of immediate-early genes such as c-fos via various signal transduction pathways. We have previously reported that promyelocytic leukemia protein (PML) is involved in the transcriptional regulation by SRF. PML is one of the well-known substrates for modification by small ubiquitin-related modifier-1 (SUMO-1) and several SUMO-1-modified proteins associate with PML. Here, we report that SRF is modified by SUMO-1 chiefly at lysine(147) within the DNA-binding domain. Substitution of this target lysine for alanine did not affect the translocation of SRF to PML-nuclear bodies. The SRF mutant augmented the transcriptional activity under Rho A-stimulated condition but not under serum-starved condition, suggesting that activated SRF is suppressed by its sumoylation. These data support the transcriptional role of SUMO-1 conjugating system in cellular serum response.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12788062     DOI: 10.1016/s0006-291x(03)00910-0

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  23 in total

1.  Modification of the erythroid transcription factor GATA-1 by SUMO-1.

Authors:  Licio Collavin; Monica Gostissa; Fabio Avolio; Paola Secco; Antonella Ronchi; Claudio Santoro; Giannino Del Sal
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-01       Impact factor: 11.205

Review 2.  Cardiac function and disease: emerging role of small ubiquitin-related modifier.

Authors:  Jun Wang
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2010-12-31

3.  5' CArG degeneracy in smooth muscle alpha-actin is required for injury-induced gene suppression in vivo.

Authors:  Jennifer A Hendrix; Brian R Wamhoff; Oliver G McDonald; Sanjay Sinha; Tadashi Yoshida; Gary K Owens
Journal:  J Clin Invest       Date:  2005-02       Impact factor: 14.808

Review 4.  SUMO wrestling with type 1 diabetes.

Authors:  Manyu Li; Dehuang Guo; Carlos M Isales; Decio L Eizirik; Mark Atkinson; Jin-Xiong She; Cong-Yi Wang
Journal:  J Mol Med (Berl)       Date:  2005-04-02       Impact factor: 4.599

5.  Serum response factor regulates expression of phosphatase and tensin homolog through a microRNA network in vascular smooth muscle cells.

Authors:  Henrick N Horita; Peter A Simpson; Allison Ostriker; Seth Furgeson; Vicki Van Putten; Mary C M Weiser-Evans; Raphael A Nemenoff
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-09-22       Impact factor: 8.311

6.  Defective sumoylation pathway directs congenital heart disease.

Authors:  Jun Wang; Li Chen; Shu Wen; Huiping Zhu; Wei Yu; Ivan P Moskowitz; Gary M Shaw; Richard H Finnell; Robert J Schwartz
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2011-05-11

Review 7.  Sumoylation and regulation of cardiac gene expression.

Authors:  Jun Wang; Robert J Schwartz
Journal:  Circ Res       Date:  2010-07-09       Impact factor: 17.367

8.  Regulation of 130-kDa smooth muscle myosin light chain kinase expression by an intronic CArG element.

Authors:  Meng Chen; Wenwu Zhang; Xiao Lu; April M Hoggatt; Susan J Gunst; Ghassan S Kassab; Johnathan D Tune; B Paul Herring
Journal:  J Biol Chem       Date:  2013-10-22       Impact factor: 5.157

9.  Regulation of cardiac specific nkx2.5 gene activity by small ubiquitin-like modifier.

Authors:  Jun Wang; Hua Zhang; Dinakar Iyer; Xin-Hua Feng; Robert J Schwartz
Journal:  J Biol Chem       Date:  2008-06-24       Impact factor: 5.157

Review 10.  A manually curated network of the PML nuclear body interactome reveals an important role for PML-NBs in SUMOylation dynamics.

Authors:  Ellen Van Damme; Kris Laukens; Thanh Hai Dang; Xaveer Van Ostade
Journal:  Int J Biol Sci       Date:  2010-01-12       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.